<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02959853</url>
  </required_header>
  <id_info>
    <org_study_id>H-36912</org_study_id>
    <nct_id>NCT02959853</nct_id>
  </id_info>
  <brief_title>Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot)</brief_title>
  <official_title>Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <brief_summary>
    <textblock>
      After the age of 40, there is a gradual decline in the production of testosterone. Among
      obese men, the decline in testosterone levels is exacerbated by the suppression of the
      hypothalamic-pituitary-gonadal axis by hyperestrogenemia. The high expression of aromatase
      enzyme in the adipose tissue enhances the conversion of androgens into estrogens which in
      turn exert a negative feedback on the hypothalamus and pituitary, leading to the inhibition
      of production of gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH) and follicle
      stimulating hormone (FSH), and as a consequence, of testosterone by the testis resulting in
      hypogonadotropic hypogonadism (HH). Though bone loss is a well recognized side effect of AI
      in certain populations, such as women with breast cancer, HH obese men present high levels of
      circulating estrogens that could potentially prevent them from bone loss, estradiol being the
      main regulator of the male skeleton. This study is designed to determine if aromatase
      inhibitors in combination with weight loss, compared to weight loss alone, will have a
      positive effect on muscle strength, symptoms of hypogonadism, and body composition without
      negatively impacting bone mineral density and bone quality. Results from this study will help
      determine if certain groups of obese patients would benefit from therapy with aromatase
      inhibitors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After the age of 40, testosterone (T) production in men gradually decreases at a rate of 1.6%
      per year for total and to 2-3% per year for bioavailable T. Because of the age-related
      increase in sex hormone binding globulin, the magnitude of the decrease in bioavailable T in
      men is even greater than the decline in total T levels. This reduction in T production in men
      parallels the age-associated loss of muscle mass that leads to sarcopenia and impairment of
      function and the age-associated loss of bone mass that leads to osteopenia and fracture risk.
      Hypogonadism is a condition associated with multiple symptom complex including fatigue,
      depressed mood, osteoporosis, increased fat mass, loss of libido and reduced muscle strength,
      all of which deeply affect patient's quality of life. The prevalence of hypogonadismamong
      obese men ranges between 29.3% to 78.8%, with levels of androgens decreasing proportionately
      to the degree of obesity. This decline in T levels is exacerbated among obese patients due
      the suppression of the hypothalamic-pituitary-gonadal axis by hyperestrogenemia. The high
      expression of aromatase enzyme in the adipose tissue enhances the conversion of androgens
      into estrogens (E) which in turn exerts a negative feedback on hypothalamus and pituitary,
      inhibiting the production of gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH)
      and follicle stimulating hormone (FSH) and, as a consequence, of T by the testis resulting in
      hypogonadotropic hypogonadism (HH). Considering the high aromatase expression in the adipose
      tissue, the administration of T among obese men with HH could increase the conversion of the
      substrate T to estradiol (E2) and fuels the negative feedback on the hypothalamus and
      pituitary, producing a greater suppression of GnRH and gonadotropins.

      Thus, men with obesity induced HH may benefit from other treatment strategies that target the
      pathophysiology of the disease. Weight loss intervention which improves hormonal and
      metabolic abnormalities related to obesity may also be considered a logical approach to
      improve obesity-induced HH.

      One possible approach consists of the use of aromatase inhibitors (AI) to stop the conversion
      of T to E2 thereby interrupting the vicious cycle of E2 inhibition of the
      hypothalamic-pituitary-gonadal axis and restoring T production to normal levels. Increased T
      and reduced E2 levels have been reported in men with low levels of T after AI administration,
      even though very few studies investigated clinical outcomes.

      We believe that AI use could promote positive changes on hypogonadal symptoms and body
      composition in HH severely obese patients, acting at the physiopathology of the disease
      without necessarily causing bone loss.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">December 20, 2018</completion_date>
  <primary_completion_date type="Actual">November 20, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Muscle Strength as Assessed by Knee Extension and Knee Flexion</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>Muscle strength was assessed using Biodex System 4 Isokinetic Dynamometer (Shirley, NY). Peak torque for isokinetic knee extension and flexion was measured at baseline, 6 months on the right leg. During the testing, participants sat with their hips flexed at 120 degrees, secured with thigh and pelvic straps. Testing was performed at an angular velocity of 60 degrees per second. The best result of 3 maximal voluntary efforts for each knee flexion and extension was used as the measure of absolute strength and reported as peak torque at 60 degrees in Newton-meter (N*m) units.
The higher the measured Newton-meter (N*m), the greater the measured muscle strength.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Symptoms Score of Hypogonadism</measure>
    <time_frame>baseline, 3 and 6 months</time_frame>
    <description>Symptoms of androgen deficiency were measured with 3 validated questionnaires done at baseline, 3 and 6 months.
The Quantitative Androgen Deficiency in the Aging Male (qADAM) questionnaire uses questions from a scale of 1-5. The final summation yields a total score between 10 (most symptomatic) and 50 (least symptomatic).
The second questionnaire used was the International Index of Erectile Function (IIEF). Total score ranges from 5 to 25, with 5 being severe erectile dysfunction and 25 being no erectile dysfunction.
The third questionnaire used was the Impact of Weight on Quality of Life Questionnaire-Lite (IWQOL-lite). Total score ranges from 31 to 155, with 31 being least symptomatic and 155 being the most symptomatic.
Score change at 3 months calculated by: total score at 3 months minus total score at baseline
Score change at 6 months calculated by: total score at 6 months minus total score at baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Fat Mass (in Kilograms)</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>change in fat was measured by Dual-energy X-ray absorptiometry (DXA) scan at baseline and 6 months only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Visceral Adipose Tissue (in Grams)</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>Change in absolute visceral adipose tissue as measured by DXA scan, done at baseline and 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Bone Mineral Density</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>Percent change in bone mineral density as measured by DXA scan, done at baseline and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Bone Quality</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>Percent change in bone quality as measured by high resolution peripheral quantitative computed tomography scan (HR-pQCT), at baseline and 6 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Hypogonadism</condition>
  <condition>Severe Obesity</condition>
  <arm_group>
    <arm_group_label>weight loss</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aromatase inhibitor (anastrazole) plus weight loss</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient placed on an aromatase inhibitor anastrazole 1 mg daily plus given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrazole</intervention_name>
    <arm_group_label>aromatase inhibitor (anastrazole) plus weight loss</arm_group_label>
    <other_name>Arimidex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>weight loss</intervention_name>
    <arm_group_label>aromatase inhibitor (anastrazole) plus weight loss</arm_group_label>
    <arm_group_label>weight loss</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  severely obese (BMI &gt;= 35) male veterans with hypogonadotropic hypogonadism defined as
             low total testosterone (lower than 300 ng/dl) between 35-65 years of age

          -  Luteinizing hormone (LH) lower than 9 U/L

          -  estradiol above 40 pmol/l

          -  normal Free T4 (FT4), Thyroid Stimulating Hormone (TSH), prolactin, cortisol,
             Adrenocorticotropic hormone (ACTH), and Insulin-like growth factor-1 (IGF-1) levels.

          -  Subjects must be ambulatory, willing and able to provide written informed consent

        Exclusion Criteria:

          -  clinical or biochemical evidence of pituitary or hypothalamic disease

          -  any ongoing illness that, in the opinion of the investigator, could prevent the
             subject from completing study

          -  any med known to affect gonadal hormones, steroid hormone-binding globulin or bone
             metabolism, e.g.,

               -  androgens

               -  estrogens

               -  glucocorticoids

               -  phenytoin

               -  bisphosphonates

               -  any medication known to interfere with anastrozole metabolism, e.g. tamoxifen or
                  estrogens

          -  diseases known to interfere with bone metabolism as

               -  osteoporosis

               -  hyperparathyroidism

               -  untreated hyperthyroidism

               -  osteomalacia

               -  chronic liver disease

               -  renal failure

               -  hypercortisolism

               -  malabsorption

               -  immobilization

               -  patients with a Total T score lower than -2.0 at Lumbar Spine or Left Femur.

          -  patients with symptomatic prostate disease, prostate carcinoma, or elevated serum
             Prostate-specific antigen (PSA) &gt;4 ng/ml or &gt;3 for subjects with a family history of
             prostate cancer among 1st degree relatives needs urologic evaluation before admission
             into study

          -  hematocrit greater than 50%

          -  untreated severe obstructive sleep apnea

          -  severe lower urinary tract symptoms with International Prostate Symptom Score (IPSS)
             above 19

          -  documented heart failure

          -  cardiovascular disease

          -  liver disease

          -  excessive alcohol or substance abuse

          -  unstable weight (changes in weight more than Â± 2 kg) during the last 3 months

          -  history of bariatric surgery

          -  subjects with elevated liver enzymes as alanine transaminase (ALT), aspartate
             aminotransferase (AST), Alkaline phosphatase (ALP), and bilirubin at greater than
             twice the upper limit of normal.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reina Villareal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Michael E. DeBakey Veterans Affairs Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 3, 2016</study_first_submitted>
  <study_first_submitted_qc>November 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2016</study_first_posted>
  <results_first_submitted>November 4, 2019</results_first_submitted>
  <results_first_submitted_qc>January 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 30, 2020</results_first_posted>
  <last_update_submitted>January 20, 2020</last_update_submitted>
  <last_update_submitted_qc>January 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Rui Chen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hypogonadism</keyword>
  <keyword>Severe obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity, Morbid</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 24, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT02959853/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Weight Loss Plus Placebo</title>
          <description>Patients given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
weight loss</description>
        </group>
        <group group_id="P2">
          <title>Aromatase Inhibitor (Anastrazole) Plus Weight Loss</title>
          <description>Patient placed on an aromatase inhibitor anastrazole 1 mg daily plus given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
Anastrazole
weight loss</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>11 in the placebo plus weight loss group 12 in the aromatase inhibitor plus weight loss group</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Plus Weight Loss</title>
          <description>Patients given a placebo and counseling on diet and exercise in order to achieve a goal weight loss of 10 percent.</description>
        </group>
        <group group_id="B2">
          <title>Aromatase Inhibitor (Anastrazole) Plus Weight Loss</title>
          <description>Patient placed on an aromatase inhibitor anastrazole 1 mg daily plus given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Muscle Strength as Assessed by Knee Extension and Knee Flexion</title>
        <description>Muscle strength was assessed using Biodex System 4 Isokinetic Dynamometer (Shirley, NY). Peak torque for isokinetic knee extension and flexion was measured at baseline, 6 months on the right leg. During the testing, participants sat with their hips flexed at 120 degrees, secured with thigh and pelvic straps. Testing was performed at an angular velocity of 60 degrees per second. The best result of 3 maximal voluntary efforts for each knee flexion and extension was used as the measure of absolute strength and reported as peak torque at 60 degrees in Newton-meter (N*m) units.
The higher the measured Newton-meter (N*m), the greater the measured muscle strength.</description>
        <time_frame>baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Weight Loss</title>
            <description>Patients given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
weight loss</description>
          </group>
          <group group_id="O2">
            <title>Aromatase Inhibitor (Anastrazole) Plus Weight Loss</title>
            <description>Patient placed on an aromatase inhibitor anastrazole 1 mg daily plus given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
Anastrazole
weight loss</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Muscle Strength as Assessed by Knee Extension and Knee Flexion</title>
          <description>Muscle strength was assessed using Biodex System 4 Isokinetic Dynamometer (Shirley, NY). Peak torque for isokinetic knee extension and flexion was measured at baseline, 6 months on the right leg. During the testing, participants sat with their hips flexed at 120 degrees, secured with thigh and pelvic straps. Testing was performed at an angular velocity of 60 degrees per second. The best result of 3 maximal voluntary efforts for each knee flexion and extension was used as the measure of absolute strength and reported as peak torque at 60 degrees in Newton-meter (N*m) units.
The higher the measured Newton-meter (N*m), the greater the measured muscle strength.</description>
          <units>Percent change in muscle strength</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>percent change in knee flexion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" spread="13.3"/>
                    <measurement group_id="O2" value="8.9" spread="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>percent change in knee extension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" spread="13.8"/>
                    <measurement group_id="O2" value="3.7" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Symptoms Score of Hypogonadism</title>
        <description>Symptoms of androgen deficiency were measured with 3 validated questionnaires done at baseline, 3 and 6 months.
The Quantitative Androgen Deficiency in the Aging Male (qADAM) questionnaire uses questions from a scale of 1-5. The final summation yields a total score between 10 (most symptomatic) and 50 (least symptomatic).
The second questionnaire used was the International Index of Erectile Function (IIEF). Total score ranges from 5 to 25, with 5 being severe erectile dysfunction and 25 being no erectile dysfunction.
The third questionnaire used was the Impact of Weight on Quality of Life Questionnaire-Lite (IWQOL-lite). Total score ranges from 31 to 155, with 31 being least symptomatic and 155 being the most symptomatic.
Score change at 3 months calculated by: total score at 3 months minus total score at baseline
Score change at 6 months calculated by: total score at 6 months minus total score at baseline</description>
        <time_frame>baseline, 3 and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Weight Loss</title>
            <description>Patients given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
weight loss</description>
          </group>
          <group group_id="O2">
            <title>Aromatase Inhibitor (Anastrazole) Plus Weight Loss</title>
            <description>Patient placed on an aromatase inhibitor anastrazole 1 mg daily plus given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
Anastrazole
weight loss</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Symptoms Score of Hypogonadism</title>
          <description>Symptoms of androgen deficiency were measured with 3 validated questionnaires done at baseline, 3 and 6 months.
The Quantitative Androgen Deficiency in the Aging Male (qADAM) questionnaire uses questions from a scale of 1-5. The final summation yields a total score between 10 (most symptomatic) and 50 (least symptomatic).
The second questionnaire used was the International Index of Erectile Function (IIEF). Total score ranges from 5 to 25, with 5 being severe erectile dysfunction and 25 being no erectile dysfunction.
The third questionnaire used was the Impact of Weight on Quality of Life Questionnaire-Lite (IWQOL-lite). Total score ranges from 31 to 155, with 31 being least symptomatic and 155 being the most symptomatic.
Score change at 3 months calculated by: total score at 3 months minus total score at baseline
Score change at 6 months calculated by: total score at 6 months minus total score at baseline</description>
          <units>score on scale (qADAM, IIEF, IWQOL-lite)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>qADAM score change at 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="3.4"/>
                    <measurement group_id="O2" value="5.8" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>qADAM score change at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="5.7"/>
                    <measurement group_id="O2" value="4.4" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IIEF score change at 3 monthss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="3.8"/>
                    <measurement group_id="O2" value="2.7" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IIEF score change at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="4.11"/>
                    <measurement group_id="O2" value="1.7" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IWQOL-lite score change at 3 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.2" spread="23.9"/>
                    <measurement group_id="O2" value="-13.0" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IWQOL-lite score change at 6 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.6" spread="27.1"/>
                    <measurement group_id="O2" value="-18.6" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fat Mass (in Kilograms)</title>
        <description>change in fat was measured by Dual-energy X-ray absorptiometry (DXA) scan at baseline and 6 months only.</description>
        <time_frame>baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Weight Loss Plus Placebo</title>
            <description>Patients given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
weight loss</description>
          </group>
          <group group_id="O2">
            <title>Aromatase Inhibitor (Anastrazole) Plus Weight Loss</title>
            <description>Patient placed on an aromatase inhibitor anastrazole 1 mg daily plus given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
Anastrazole
weight loss</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fat Mass (in Kilograms)</title>
          <description>change in fat was measured by Dual-energy X-ray absorptiometry (DXA) scan at baseline and 6 months only.</description>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="1.9"/>
                    <measurement group_id="O2" value="-4.4" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Visceral Adipose Tissue (in Grams)</title>
        <description>Change in absolute visceral adipose tissue as measured by DXA scan, done at baseline and 6 months.</description>
        <time_frame>baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Weight Loss Plus Placebo</title>
            <description>Patients given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
weight loss</description>
          </group>
          <group group_id="O2">
            <title>Aromatase Inhibitor (Anastrazole) Plus Weight Loss</title>
            <description>Patient placed on an aromatase inhibitor anastrazole 1 mg daily plus given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
Anastrazole
weight loss</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visceral Adipose Tissue (in Grams)</title>
          <description>Change in absolute visceral adipose tissue as measured by DXA scan, done at baseline and 6 months.</description>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9" spread="81.6"/>
                    <measurement group_id="O2" value="-111.7" spread="258.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Bone Mineral Density</title>
        <description>Percent change in bone mineral density as measured by DXA scan, done at baseline and 6 months</description>
        <time_frame>baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Weight Loss Plus Placebo</title>
            <description>Patients given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
weight loss</description>
          </group>
          <group group_id="O2">
            <title>Aromatase Inhibitor (Anastrazole) Plus Weight Loss</title>
            <description>Patient placed on an aromatase inhibitor anastrazole 1 mg daily plus given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
Anastrazole
weight loss</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Bone Mineral Density</title>
          <description>Percent change in bone mineral density as measured by DXA scan, done at baseline and 6 months</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>percent change in total hip bone density</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.45" spread="3.98"/>
                    <measurement group_id="O2" value="-0.46" spread="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>percent change in femoral neck bone density</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.63" spread="2.92"/>
                    <measurement group_id="O2" value="0.82" spread="3.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>percent change in lumbar spine bone density</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.22" spread="4.89"/>
                    <measurement group_id="O2" value="-0.71" spread="3.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Bone Quality</title>
        <description>Percent change in bone quality as measured by high resolution peripheral quantitative computed tomography scan (HR-pQCT), at baseline and 6 months</description>
        <time_frame>baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Weight Loss Plus Placebo</title>
            <description>Patients given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
weight loss</description>
          </group>
          <group group_id="O2">
            <title>Aromatase Inhibitor (Anastrazole) Plus Weight Loss</title>
            <description>Patient placed on an aromatase inhibitor anastrazole 1 mg daily plus given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
Anastrazole
weight loss</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Bone Quality</title>
          <description>Percent change in bone quality as measured by high resolution peripheral quantitative computed tomography scan (HR-pQCT), at baseline and 6 months</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>percent change in failure load at the radius</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.16" spread="3.09"/>
                    <measurement group_id="O2" value="-4.63" spread="6.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>percent change in bone stiffness at the radius</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.09" spread="3.29"/>
                    <measurement group_id="O2" value="-4.02" spread="6.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>percent change in failure load at the tibia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="2.9"/>
                    <measurement group_id="O2" value="-0.81" spread="4.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>percent change in bone stiffness at the tibia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="3.28"/>
                    <measurement group_id="O2" value="-1.31" spread="5.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <desc>see data tables</desc>
      <group_list>
        <group group_id="E1">
          <title>Weight Loss</title>
          <description>Patients given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
weight loss</description>
        </group>
        <group group_id="E2">
          <title>Aromatase Inhibitor (Anastrazole) Plus Weight Loss</title>
          <description>Patient placed on an aromatase inhibitor anastrazole 1 mg daily plus given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
Anastrazole
weight loss</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hospital</sub_title>
                <description>Admitted for low back pain</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hospital admission</sub_title>
                <description>034 admitted for suicidal ideation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>uncontrolled DM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>shoulder pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>heel pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rui Chen</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <phone>812-239-1855</phone>
      <email>rui.chen2@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

